APOBEC	O
signature	O
mutation	O
generates	O
an	O
oncogenic	B-ENHANCER
enhancer	E-ENHANCER
that	O
drives	O
LMO1	O
expression	O
in	O
T	O
-	O
ALL	O
.	O


Oncogenic	O
driver	O
mutations	O
are	O
those	O
that	O
provide	O
a	O
proliferative	O
or	O
survival	O
advantage	O
to	O
neoplastic	O
cells	O
,	O
resulting	O
in	O
clonal	O
selection	O
.	O


Although	O
most	O
cancer	O
-	O
causing	O
mutations	O
have	O
been	O
detected	O
in	O
the	O
protein	O
-	O
coding	O
regions	O
of	O
the	O
cancer	O
genome	O
;	O
driver	O
mutations	O
have	O
recently	O
also	O
been	O
discovered	O
within	O
noncoding	O
genomic	O
sequences	O
.	O


Thus	O
,	O
a	O
current	O
challenge	O
is	O
to	O
gain	O
precise	O
understanding	O
of	O
how	O
these	O
unique	O
genomic	O
elements	O
function	O
in	O
cancer	O
pathogenesis	O
,	O
while	O
clarifying	O
mechanisms	O
of	O
gene	O
regulation	O
and	O
identifying	O
new	O
targets	O
for	O
therapeutic	O
intervention	O
.	O


Here	O
we	O
report	O
a	O
C	O
-	O
to	O
-	O
T	O
single	O
nucleotide	O
transition	O
that	O
occurs	O
as	O
a	O
somatic	O
mutation	O
in	O
noncoding	O
sequences	O
4	O
kb	O
upstream	O
of	O
the	O
transcriptional	O
start	O
site	O
of	O
the	O
LMO1	O
oncogene	O
in	O
primary	O
samples	O
from	O
patients	O
with	O
T	O
-	O
cell	O
acute	O
lymphoblastic	O
leukaemia	O
.	O


This	O
single	O
nucleotide	O
alteration	O
conforms	O
to	O
an	O
APOBEC	O
-	O
like	O
cytidine	O
deaminase	O
mutational	O
signature	O
,	O
and	O
generates	O
a	O
new	O
binding	O
site	O
for	O
the	O
MYB	O
transcription	O
factor	O
,	O
leading	O
to	O
the	O
formation	O
of	O
an	O
aberrant	O
transcriptional	B-ENHANCER
enhancer	I-ENHANCER
complex	E-ENHANCER
that	O
drives	O
high	O
levels	O
of	O
expression	O
of	O
the	O
LMO1	O
oncogene	O
.	O


Since	O
APOBEC	O
-	O
signature	O
mutations	O
are	O
common	O
in	O
a	O
broad	O
spectrum	O
of	O
human	O
cancers	O
,	O
we	O
suggest	O
that	O
noncoding	O
nucleotide	O
transitions	O
such	O
as	O
the	O
one	O
described	O
here	O
may	O
activate	O
potent	O
oncogenic	O
enhancers	O
not	O
only	O
in	O
T	O
-	O
lymphoid	O
cells	O
but	O
in	O
other	O
cell	O
lineages	O
as	O
well	O
.	O
